CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis.

[1]  T. Olsson,et al.  Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[2]  A. Uccelli,et al.  Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program , 2020, Frontiers in Neurology.

[3]  H. Reiber,et al.  Diagnostic relevance of free light chains in cerebrospinal fluid - The hyperbolic reference range for reliable data interpretation in quotient diagrams. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[4]  H. Tumani,et al.  Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis , 2019, Clinical chemistry and laboratory medicine.

[5]  X. Montalban,et al.  Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study , 2019, Multiple sclerosis.

[6]  V. Tomassini,et al.  Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis , 2019, JAMA neurology.

[7]  F. Deisenhammer,et al.  The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review , 2019, PloS one.

[8]  A. Ludolph,et al.  CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort , 2019, Front. Immunol..

[9]  T. Witte,et al.  The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis , 2018, International journal of molecular sciences.

[10]  D. Murray,et al.  CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes , 2018, Clinical chemistry and laboratory medicine.

[11]  X. Montalban,et al.  Ocrelizumab: a new milestone in multiple sclerosis therapy , 2018, Therapeutic advances in neurological disorders.

[12]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[13]  G. Salanti,et al.  Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. , 2017, The Cochrane database of systematic reviews.

[14]  G. Bellomo,et al.  Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs. , 2017, Clinical laboratory.

[15]  V. Martinelli,et al.  Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis , 2016, Multiple sclerosis international.

[16]  J. Katzmann,et al.  Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias , 2016, Clinical chemistry and laboratory medicine.

[17]  H. Tumani,et al.  Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study , 2016, Multiple sclerosis.

[18]  A. Cross,et al.  Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. , 2016, JAMA neurology.

[19]  B. Hemmer,et al.  B cell-directed therapies in multiple sclerosis. , 2016, Neurodegenerative disease management.

[20]  O. Ciccarelli,et al.  Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study , 2015, Multiple sclerosis.

[21]  M. Bonnan,et al.  Intrathecal IgG Synthesis: A Resistant and Valuable Target for Future Multiple Sclerosis Treatments , 2015, Multiple sclerosis international.

[22]  S. Curnow,et al.  High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis , 2014, Journal of Neuroimmunology.

[23]  S. Baranzini,et al.  Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients , 2014, The Journal of Immunology.

[24]  H. Tumani,et al.  Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis , 2014, PloS one.

[25]  S. Presslauer,et al.  Kappa Free Light Chains: Diagnostic and Prognostic Relevance in MS and CIS , 2014, PloS one.

[26]  Ewout Steyerberg,et al.  Net Reclassification Improvement: Computation, Interpretation, and Controversies , 2014, Annals of Internal Medicine.

[27]  D. Centonze,et al.  Determination of kFLC and K Index in cerebrospinal fluid: A valid alternative to assessintrathecal immunoglobulin synthesis , 2013, Journal of Neuroimmunology.

[28]  A. Sadovnick,et al.  Epidemiology of multiple sclerosis. , 2011, Neurologic clinics.

[29]  F. Birklein,et al.  High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid , 2009, Acta neurologica Scandinavica.

[30]  M. Salvetti,et al.  B cells and multiple sclerosis , 2008, The Lancet Neurology.

[31]  T. Brücke,et al.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis , 2008, Journal of Neurology.

[32]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[33]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[34]  D. Bernard,et al.  Quantification of Immunoglobulin Free Light Chains in CerebroSpinal Fluid by Nephelometry , 2005, Journal of Clinical Immunology.

[35]  Gavin Giovannoni,et al.  Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. , 2005, Archives of neurology.

[36]  P. Bossuyt,et al.  The diagnostic odds ratio: a single indicator of test performance. , 2003, Journal of clinical epidemiology.

[37]  B. Weinshenker,et al.  Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index. , 2003, American journal of clinical pathology.

[38]  G. Bernardi,et al.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[39]  E. Thompson,et al.  Isoelectric focusing versus quantitative measurements in the detection of intrathecal local synthesis of IgG. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[40]  V. Kostulas,et al.  Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. , 1987, Archives of neurology.

[41]  C. DeCarli,et al.  Free light chains in multiple sclerosis and infections of the CNS , 1987, Neurology.

[42]  P. A. R. Koopman,et al.  Confidence intervals for the ratio of two binomial proportions , 1984 .

[43]  D. Hafler,et al.  Multiple sclerosis. , 2012, The Journal of clinical investigation.